Prescription medicine
Avibactam and ceftazidime Brand names: Avycaz
Avibactam and ceftazidime (Avycaz) is a prescription medicine with an FDA approval on record since 2015. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the avibactam and ceftazidime FDA label on DailyMed (effective April 30, 2025, Allergan, Inc.); the NDA 206494 record on Drugs@FDA; every avibactam and ceftazidime label on DailyMed.
Highlights of the record
FDA label of April 30, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageAVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible Gram-negative microorganisms in adult and pediatric patients (at least 31 weeks gestational age): Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole ( 1.1 ) Complicated Urinary Tract Infections (c
Forms and strengths
- 2 g / 0.5 g
Powder for solution.
On the market
- Earliest approval on file
- February 25, 2015 Avycaz, Abbvie; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- June 15, 2032 Avycaz injection; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 163 through July 30, 2026
What is avibactam and ceftazidime used for?
From the label: indications and usageAVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible Gram-negative microorganisms in adult and pediatric patients (at least 31 weeks gestational age): Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole ( 1.1 ) Complicated Urinary Tract Infections (cUTI), including Pyelonephritis ( 1.2 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVYCAZ and other antibacterial drugs, AVYCAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. […]
Conditions named in the indications of avibactam and ceftazidime's FDA labels, with every medicine labeled for each:
From other avibactam and ceftazidime labelsUrinary tract infections: Complicated Urinary Tract Infections ( cUTI ), including Pyelonephritis AVYCAZ (ceftazidime and avibactam) is indicated for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis in adult and pediatric …
FDA pharmacologic class: Cephalosporin Antibacterial and beta Lactamase Inhibitor.
Source: FDA drug label (AVYCAZ), NDA206494 (Abbvie), as published by Allergan, Inc., effective April 30, 2025 (SPL set d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd), via openFDA; the full label on DailyMed
Is there a generic for avibactam and ceftazidime (Avycaz)?
No generic avibactam and ceftazidime is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 7 patents for Avycaz injection: the compound patent runs to June 15, 2032. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2015 earliest approval on file
- 2032 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the avibactam and ceftazidime label say about other medicines?
The avibactam and ceftazidime label names 3 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Meropenem | warnings and precautions | AVYCAZ + Metronidazole % (n/N); Meropenem % (n/N) |
| Metronidazole | warnings and precautions | The reduction in clinical cure rates was more marked in patients treated with AVYCAZ plus metronidazole compared to meropenem-treated patients. |
| Probenecid | drug interactions | As a potent OAT inhibitor, probenecid inhibits OAT uptake of avibactam by 56% to 70% in vitro and, therefore, has the potential to decrease the elimination of avibactam when co-administered. |
Source: FDA drug label (AVYCAZ), NDA206494 (Abbvie), as published by Allergan, Inc., effective April 30, 2025 (SPL set d9c2803f-dc9c-4b19-b4a3-8303bc8c15fd), via openFDA; the full label on DailyMed
What do FAERS reports show for avibactam and ceftazidime?
The FDA Adverse Event Reporting System holds 163 reports that list avibactam and ceftazidime among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 16 are coded as a death and 33 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as avibactam and ceftazidime?
14 other medicines are given the same way (intravenous) and in the same FDA class as avibactam and ceftazidime or labeled mainly for the same use (urinary tract infections), the same class first. Urinary tract infections lists all 39 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Cefazolin | Urinary tract infections | 7 labelers | $1.07 per vial 1 g vial | No current entry |
| Cefepime | Urinary tract infections | 8 labelers | n/a | A presentation being discontinued |
| Cefoxitin | Urinary tract infections | 5 labelers | n/a | No current entry |
| Ceftriaxone | Urinary tract infections | 7 labelers | $1.44 per vial 1 g vial | No current entry |
| Cefuroxime | Urinary tract infections | 2 labelers | n/a | No current entry |
| Cefepime and zidebactam | Urinary tract infections | none listed | n/a | No current entry |
| Cefiderocol | Urinary tract infections | none listed | n/a | No current entry |
| Ceftolozane and tazobactam | Urinary tract infections | none listed | n/a | No current entry |
Every medicine labeled for the same conditions as avibactam and ceftazidime
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to avibactam and ceftazidime
- 14 medicines for the same use
- Other cephalosporins
- the pharmacologic class, with prices and generics
- Avibactam and ceftazidime side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other